Literature DB >> 26960160

Delayed yet persistent effects of daily risperidone on activity in developing rats.

Rachel M Stevens1, Matthew A Gannon, Molly S Griffith, Mark E Bardgett.   

Abstract

Early-life administration of risperidone, the most widely used antipsychotic drug in children, leads to persistently elevated locomotor activity in adult rats. This study determined whether and when elevated locomotor activity emerges during developmental risperidone administration. Developing and adult rats were administered daily injections of risperidone (1.0 and 3.0 mg/kg) or vehicle for 4 weeks beginning at postnatal days 14 and 74, respectively. Starting with the first injection and every 7 days thereafter, locomotor activity was measured immediately after the injection and 20 min before the next day's injection. Activity was also recorded 1 week after the final injection. Risperidone markedly decreased locomotor activity in developing and adult rats immediately after injection. Within 24 h after their first injection, adult rats administered risperidone showed greater activity levels. In contrast, developing rats did not show compensatory hyperactivity until the beginning of the fourth week of risperidone administration. One week after the final risperidone injection, there was no evidence of hyperactivity in the adult rats maintained on risperidone, but developing rats administered risperidone, especially females, showed greater activity levels relative to vehicle-administered controls. In comparison with adult rats, the emergence of compensatory hyperactivity during long-term antipsychotic drug administration is delayed in developing rats, but persists after treatment cessation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26960160      PMCID: PMC4935566          DOI: 10.1097/FBP.0000000000000230

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  48 in total

Review 1.  Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain.

Authors:  F I Tarazi; R J Baldessarini
Journal:  Int J Dev Neurosci       Date:  2000-02       Impact factor: 2.457

2.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

3.  The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole.

Authors:  Stephanie K Thacker; Marla K Perna; Jeffery J Ward; Tori L Schaefer; Michael T Williams; Richard M Kostrzewa; Russell W Brown
Journal:  Eur J Neurosci       Date:  2006-10       Impact factor: 3.386

4.  Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate.

Authors:  M C Nowycky; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

5.  Use of antipsychotic drugs among Dutch youths between 1997 and 2005.

Authors:  Luuk J Kalverdijk; Hilde Tobi; Paul B van den Berg; Janelle Buiskool; Leonie Wagenaar; Ruud B Minderaa; Lolkje T W de Jong-van den Berg
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

6.  Chronic cocaine dampens dopamine signaling during cocaine intoxication and unbalances D1 over D2 receptor signaling.

Authors:  Kicheon Park; Nora D Volkow; Yingtian Pan; Congwu Du
Journal:  J Neurosci       Date:  2013-10-02       Impact factor: 6.167

7.  Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.

Authors:  Christina Kurre Olsen; Lise Tøttrup Brennum; Mads Kreilgaard
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

Review 8.  Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.

Authors:  Benedetto Vitiello; Christoph Correll; Barbara van Zwieten-Boot; Alessandro Zuddas; Mara Parellada; Celso Arango
Journal:  Eur Neuropsychopharmacol       Date:  2009-05-24       Impact factor: 4.600

9.  Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats.

Authors:  Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2007-09-26       Impact factor: 4.432

10.  Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine.

Authors:  J Arnt
Journal:  Eur J Pharmacol       Date:  1995-09-05       Impact factor: 4.432

View more
  1 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.